Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 26 Results

Title
Intervention Indication Therapeutic Area Year Actions
Toripalimab with chemotherapy for previously untreated recurrent or metastatic nasopharyngeal carcinoma Chemotherapy , Toripalimab Nasopharyngeal carcinoma Head and Neck Cancer 2023 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line Chemotherapy , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2020 View  |  Download
Pembrolizumab with radiotherapy and chemotherapy for treating unresectable oesophageal cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) , Radiotherapy Oesophageal cancer Head and Neck Cancer 2023 View  |  Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Gastroesophageal adenocarcinoma Gastrointestinal Cancer 2023 View  |  Download
Pembrolizumab with chemotherapy for treating advanced or recurrent endometrial cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Endometrial cancer Female Reproductive Cancer 2023 View  |  Download
Pembrolizumab with chemotherapy for platinum-resistant recurrent ovarian cancer after 1 or 2 therapies Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Ovarian cancer Female Reproductive Cancer 2023 View  |  Download
Pembrolizumab with chemotherapy for HR+/HER2- locally recurrent inoperable or metastatic breast cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Breast cancer Breast Cancer 2023 View  |  Download
Pembrolizumab perioperative therapy with neoadjuvant chemotherapy for treating cisplatin eligible muscle-invasive bladder cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2022 View  |  Download
Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications